磁共振弹性成像测得的肝脏硬度可预测索拉非尼治疗的晚期肝细胞癌预后
本研究从慢性肝病前瞻性队列中选取50例索拉非尼治疗的晚期肝细胞癌患者,分析磁共振弹性成像(MRE)测得的肝脏硬度(LS)与总生存期(OS)、无进展生存期(PFS)及显著肝损伤的关系。结果显示,较高的MRE-LS(每kPa及>7.5 kPa)与较差OS和索拉非尼治疗后显著肝损伤独立相关。
要点
- 治疗前MRE-LS>7.5 kPa与索拉非尼治疗的晚期肝细胞癌患者较差总生存期独立相关(HR 4.06)。
- 治疗前MRE-LS>7.5 kPa与索拉非尼治疗期间发生显著(≥3级)肝损伤独立相关(HR 10.11)。
- MRE-LS与无进展生存期无显著关联,AFP≥400 ng/mL和mUICC IVb期是早期疾病进展的显著危险因素。
核心结论
- 较高的MRE测得的肝脏硬度可能是预测索拉非尼治疗的晚期肝细胞癌患者较差总生存期和显著肝损伤的潜在生物标志物。
研究设计与样本
- 研究类型为从慢性肝病患者前瞻性维护队列中筛选患者的预后分析,样本量为50例索拉非尼治疗的晚期肝细胞癌患者。
- 纳入标准为在索拉非尼给药前3个月内接受MRE检查,采用单因素和多因素分析评估实验室数据、肿瘤特征及MRE测得的肝脏硬度对总生存期、无进展生存期和索拉非尼给药后显著肝损伤(≥3级)的预后作用。
诊断标准与关键数值
- MRE测得的肝脏硬度作为连续变量(每kPa)与较差总生存期显著相关(HR 1.54,95%CI 1.23-1.92,p<0.001)。
- MRE测得的肝脏硬度作为分类变量(>7.5 kPa)与较差总生存期显著相关(HR 4.06,95%CI 1.40-11.79,p<0.01)。
- MRE测得的肝脏硬度作为连续变量(每kPa)与索拉非尼给药后显著肝损伤显著相关(HR 1.62,95%CI 1.21-2.17,p=0.001)。
- MRE测得的肝脏硬度作为分类变量(>7.5 kPa)与索拉非尼给药后显著肝损伤显著相关(HR 10.11,95%CI 2.41-42.46,p=0.002)。
- 血清AFP≥400 ng/mL和晚期肿瘤分期(mUICC IVb)与较差总生存期显著相关,且为无进展生存期早期疾病进展的显著危险因素;肝脏硬度与无进展生存期无显著关联。
临床应用与阅片要点
- 对于索拉非尼治疗的晚期肝细胞癌患者,治疗前MRE测得的肝脏硬度>7.5 kPa提示总生存期较差且治疗期间发生显著(≥3级)肝损伤的风险较高。
- 作者指出,治疗前MRE测得的肝脏硬度较高的患者在索拉非尼治疗期间应仔细监测潜在的肝损伤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: We investigated whether liver stiffness (LS) quantified using magnetic resonance elastography (MRE) could predict the prognosis of advanced hepatocellular carcinoma (HCC) patients treated with sorafenib.
METHODS: We selected 50 sorafenib-treated advanced HCC patients who underwent MRE within 3 months before drug administration from a prospectively maintained cohort of chronic liver disease patients, according to the inclusion and exclusion criteria. Univariate and multivariate analyses were performed to evaluate the prognostic role of laboratory data, tumor characteristics, and MRE-assessed LS for overall survival (OS), progression-free survival (PFS), and significant liver injury (grade ≥ 3) after sorafenib administration.
RESULTS: High MRE-assessed LS either as continuous (per kPa, hazard ratio (HR) 1.54; 95% confidence interval (CI) 1.23-1.92, p < 0.001) or categorical (> 7.5 kPa, HR 4.06, 95% CI 1.40-11.79, p < 0.01) variable was significantly associated with poor OS along with higher serum alpha-fetoprotein (AFP, ≥ 400 ng/mL) and advanced tumor stage (modified Union for International Cancer Control (mUICC) IVb). Higher MRE-assessed LS was also significantly associated with the development of significant liver injury after sorafenib administration (per kPa, HR 1.62, 95% CI 1.21-2.17, p = 0.001; > 7.5 kPa, HR 10.11, 95% CI 2.41-42.46, p = 0.002). PFS analysis identified higher serum AFP (≥ 400 ng/mL) and advanced tumor stage (mUICC IVb) as significant risk factors for early disease progression, whereas LS was not associated with PFS CONCLUSION: Higher MRE-assessed LS is a potential biomarker for predicting poor OS and significant liver injury in advanced HCC patients treated with sorafenib.
KEY POINTS: • Higher pretreatment LS by MRE (> 7.5 kPa), higher AFP (≥ 400 ng/mL), and advanced tumor stage (mUICC IVb) were associated with poor OS in advanced HCC patients treated with sorafenib. • Higher pretreatment LS by MRE was associated with developing significant (grade ≥ 3) liver injury during sorafenib treatment, which required termination of the therapy. • Patients with high pretreatment LS by MRE should be monitored carefully for potential liver injury during sorafenib treatment.
引用
- Kim B, Kim SS, Cho SW, et al. Liver stiffness in magnetic resonance elastography is prognostic for sorafenib-treated advanced hepatocellular carcinoma. Eur Radiol. 2020. PMID: 33033862. doi:10.1007/s00330-020-07357-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。